Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center

November 5, 2020
Pharmaceutical Technology Editors

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter 11-04-2020, Volume 15, Issue 11

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.

Samsung Biologics has integrated Solentim’s VIPS single cell seeding platform and Cell Metric CLD platform to its R&D facility in San Francisco, CA. These instruments are designed for single-cell cloning and can ensure monoclonality to increase the speed and efficiency of master cell bank development.

With the additions, Samsung’s San Francisco R&D facility can offer rapid, high quality development services, including cell line development. Solentim’s VIPS and Cell Metric CLD instruments will be used in conjunction with Samsung Biologics’ recently launched proprietary cell line platform, S-CHOice, which Samsung Biologics debuted in September 2020. The VIPS and Cell Metric CLD platforms were added in October 2020.

“We’re pleased to extend our long-standing partnership with Samsung Biologics, which has previously purchased and enjoyed success with our equipment in its headquarter operations,” said Mark Truesdale, CEO of Solentim, in an Oct. 7, 2020 company press release.

Source: Solentim